MORF Morphic Holding Inc.

19.36
+0.4  (+2%)
Previous Close 18.96
Open 18.66
Price To Book 3.7
Market Cap 590,160,967
Shares 30,483,521
Volume 138,066
Short Ratio
Av. Daily Volume 59,637
Stock charts supplied by TradingView

NewsSee all news

  1. Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,

  2. Morphic to Present at the Jefferies 2019 London Healthcare Conference

    WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,

  3. Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results

    MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third quarter of 2019 with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

IND filing due late-2019.
MORF-720
Idiopathic pulmonary fibrosis
IND filing due mid-2020.
MRb7 #1
inflammatory bowel disease

Latest News

  1. Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,

  2. Morphic to Present at the Jefferies 2019 London Healthcare Conference

    WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,

  3. Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results

    MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third quarter of 2019 with